Care for life, Focus on innovation, win win cooperation

Leads Biolabs is a clinical-stage biotechnology company

dedicated to the discovery, development, and commercialization of innovative therapies

to address underserved medical needs in oncology, autoimmune, and other severe diseases both in China and globally.

2012

YEAR FOUNDED
80%+

R&D PERSONNEL
20+

PIPELINE ASSETS
20

PATENTS GRANTED

Front-Runner in Next-Gen Immuno-Oncology Treatments

Multiple Clinical Programs
For cancer patients who do not respond adequately to existing immunotherapies
Differentiated Pipeline
Uniquely designed to form an ecosystem of comprehensive therapeutics
Integrated Capabilities
Across early discovery, clinical development, CMC and business development

Clinical trial results of Leads Biolabs' LBL-007（anti-LAG-3 mAb）combined with anti-PD-1 mAb in advanced nasopharyngeal carcinoma and other solid tumors published in Journal of Hematology & Oncology

In February 2025, the Phase Ib/II clinical trial results of LBL-007, a novel LAG-3 antibody independently developed by Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs"), was published in the prestigious Journal of Hematology & Oncology (Impact Factor: 29.9). This study, le

Leads Biolabs to Present Encouraging Clinical Data on Innovative Bispecific Antibody LBL-034 at the 66th ASH Annual Meeting

The 66th Annual Meeting of the American Society of Hematology (ASH 2024) will take place in San Diego, California, from December 7th to 10th. LBL-034, a humanized bispecific T-cell engager targeting both GPRC5D and CD3 which is independently developed by Nanjing Leads Biolabs Co., Ltd. (hereinafter

FDA Granted Orphan Drug Designation of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs, for Treatment of Neuroendocrine Cancer

NANJING, China, November 22, 2024 -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by the company with global intellectual property rights for the treatment of neuroendocrine cancer

Clinical trial results of Leads Biolabs' LBL-007（anti-LAG-3 mAb）combined with anti-PD-1 mAb in advanced nasopharyngeal carcinoma and other solid tumors published in Journal of Hematology & Oncology

Leads Biolabs to Present Encouraging Clinical Data on Innovative Bispecific Antibody LBL-034 at the 66th ASH Annual Meeting

FDA Granted Orphan Drug Designation of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs, for Treatment of Neuroendocrine Cancer

About Us

Pipeline

Platforms

Collaborations

News

Careers